These studies were carried out with exenatide and liraglutide in a rat model of diabetes, and they increased concerns with respect to the possible adverse effects of GLP-1 mimetic therapy on exocrine pancreas
Cholelithiasis and markers of nonalcoholic fatty liver disease in patients with metabolic risk factors
Key markers include GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313
Diabetes, Obesity and Metabolism , 19 (7), 1116-1125
Safety, Side Effects, and Monitoring Considerations The most common side effects of semaglutidenausea, vomiting, and mild gastrointestinal discomforttypically diminish within 2-4 weeks as your body adapts
The manufacturer, distributor, and retailer assume no liability for improper use, adverse reactions, or outcomes resulting from use of this product